汽車股拉昇 中汽協公佈1月新能源汽車銷量同比增238.5%
格隆匯2月9日丨福田汽車一早漲停,東風汽車拉昇漲近7%,北汽藍谷、中國汽研、曙光股份、長城汽車均現拉昇走勢。中汽協表示,2021年1月,汽車產銷分別完成238.8萬輛和250.3萬輛,環比分別下降15.9%和11.6%,同比分別增長34.6%和29.5%。其中乘用車2021年1月銷量204.5萬輛,增長26.8%;新能源汽車1月銷量17.9萬輛,增長238.5%。本月產銷同比呈現大幅增長的原因有兩點,一是當前市場需求仍在恢復,二是由於2020年春節假期在1月,加之去年年初疫情影響,因此基數水平較低。從環比來看,生產環比降幅較快反映出汽車芯片供應不足影響到企業生產節奏。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.